Expression and prognostic significance of CTBP2 in human gliomas

Wang,Yong; Che,Shusheng; Cai,Gang; He,Yuchao; Chen,Jialei; Xu,Wei

doi:10.3892/ol.2016.4998

Expression and prognostic significance of CTBP2 in human gliomas

Authors:
- Yong Wang
- Shusheng Che
- Gang Cai
- Yuchao He
- Jialei Chen
- Wei Xu
View Affiliations

Affiliations: Department of Neurosurgery, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Neurosurgery, The Affiliated Hospital of Qingdao Medical College, Qingdao University, Qingdao, Shandong 266003, P.R. China
Published online on: August 11, 2016 https://doi.org/10.3892/ol.2016.4998
Pages: 2429-2434
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Deregulated expression of C-terminal-binding protein 2 (CTBP2) has been observed previously in a number of tumors, such as hepatocellular carcinoma and prostatic cancer, in the colorectal cancer SW480 cell line and in the human embryonic kidney 293 cell line. In the present study, western blot analysis and immunohistochemistry were performed to investigate whether gliomas exhibit deregulated CTBP2 expression. Kaplan‑Meier survival analyses were performed to evaluate the associations between CTBP2 expression, clinicopathological data and patient survival in glioma patients. The results revealed that CTBP2 expression was significantly upregulated in high grade glioma tissues compared with that in low grade glioma and normal brain tissues. Furthermore, increased CTBP2 expression in gliomas was significantly associated with a higher World Health Organization (WHO) tumor grade (P<0.005) and poorer disease‑specific survival (P<0.005). In conclusion, these results suggest that CTBP2 may act as an intrinsic regulator of progression in glioma cells and thus may serve as an important prognostic factor for the disease.

View Figures

View References

1	Claes A, Idema AJ and Wesseling P: Diffuse glioma growth: A guerilla war. Acta Neuropathol. 114:443–458. 2007. View Article : Google Scholar : PubMed/NCBI
2	Wen PY, Fine HA, Black PM, Shrieve DC, Alexander E III and Loeffler JS: High-grade astrocytomas. Neurol Clin. 13:875–900. 1995.PubMed/NCBI
3	Kleihues P, Soylemezoglu F, Schäuble B, Scheithauer BW and Burger PC: Histopathology, classification, and grading of gliomas. Glia. 15:211–221. 1995. View Article : Google Scholar : PubMed/NCBI
4	Ostrom QT, Gittleman H, Farah P, et al: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 15(Suppl 2): ii1–ii56. 2013. View Article : Google Scholar : PubMed/NCBI
5	Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB and Rich JN: Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 68:6043–6048. 2008. View Article : Google Scholar : PubMed/NCBI
6	Yuan X, Curtin J, Xiong Y, Liu G, Hogiu S Waschsmann, Farkas DL, Black KL and Yu JS: Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 23:9392–9400. 2004. View Article : Google Scholar : PubMed/NCBI
7	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
8	Holland EC: Glioblastoma multiforme: The terminator. Proc Natl Acad Sci USA. 97:6242–6244. 2000. View Article : Google Scholar : PubMed/NCBI
9	Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S and Chinnadurai G: A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J. 12:469–478. 1993.PubMed/NCBI
10	Bergman LM and Blaydes JP: C-terminal binding proteins: Emerging roles in cell survival and tumorigenesis. Apoptosis. 11:879–888. 2006. View Article : Google Scholar : PubMed/NCBI
11	Chinnadurai G: The transcriptional corepressor CtBP: A foe of multiple tumor suppressors. Cancer Res. 69:731–734. 2009. View Article : Google Scholar : PubMed/NCBI
12	Corda D, Colanzi A and Luini A: The multiple activities of CtBP/BARS proteins: The Golgi view. Trends Cell Biol. 16:167–173. 2006. View Article : Google Scholar : PubMed/NCBI
13	Meloni AR, Smith EJ and Nevins JR: A mechanism for Rb/p130-mediated transcription repression involving recruitment of the CtBP corepressor. Proc Natl Acad Sci USA. 96:9574–9579. 1999. View Article : Google Scholar : PubMed/NCBI
14	Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K and Hirai H: The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood. 97:2815–2822. 2001. View Article : Google Scholar : PubMed/NCBI
15	Hamada F and Bienz M: The APC tumor suppressor binds to C-terminal binding protein to divert nuclear beta-catenin from TCF. Dev Cell. 7:677–685. 2004. View Article : Google Scholar : PubMed/NCBI
16	Van Hateren N, Shenton T and Borycki AG: Expression of avian C-terminal binding proteins (Ctbp1 and Ctbp2) during embryonic development. Dev Dyn. 235:490–495. 2006. View Article : Google Scholar
17	Hildebrand JD and Soriano P: Overlapping and unique roles for C-terminal binding protein 1 (CtBP1) and CtBP2 during mouse development. Mol Cell Biol. 22:5296–5307. 2002. View Article : Google Scholar : PubMed/NCBI
18	Chinnadurai G: CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Mol Cell. 9:213–224. 2002. View Article : Google Scholar : PubMed/NCBI
19	Paliwal S, Kovi RC, Nath B, Chen YW, Lewis BC and Grossman SR: The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor. Cancer Res. 67:9322–9329. 2007. View Article : Google Scholar : PubMed/NCBI
20	Mor V, Laliberte L, Morris JN and Wiemann M: The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 53:2002–2007. 1984. View Article : Google Scholar : PubMed/NCBI
21	Fuller GN and Scheithauer BW: The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: Newly codified entities. Brain Pathol. 17:304–307. 2007. View Article : Google Scholar : PubMed/NCBI
22	Liu R, Liu X, Zheng Y, Gu J, Xiong S, Jiang P, Jiang X, Huang E, Yang Y, Ge D and Chu Y: MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel. Oncol Lett. 8:2193–2200. 2014.PubMed/NCBI
23	Soffietti R, Bertero L, Pinessi L and Rudà R: Pharmacologic therapies for malignant glioma: A guide for clinicians. CNS Drugs. 28:1127–1137. 2014. View Article : Google Scholar : PubMed/NCBI
24	Wu CX, Lin GS, Lin ZX, Zhang JD, Chen L, Liu SY, Tang WL, Qiu XX and Zhou CF: Peritumoral edema on magnetic resonance imaging predicts a poor clinical outcome in malignant glioma. Oncology letters. 10:2769–2776. 2015.PubMed/NCBI
25	Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG and Parada LF: A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 488:522–526. 2012. View Article : Google Scholar : PubMed/NCBI
26	Kovi RC, Paliwal S, Pande S and Grossman SR: An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis. Cell Death Differ. 17:513–521. 2010. View Article : Google Scholar : PubMed/NCBI
27	Mirnezami AH, Campbell SJ, Darley M, Primrose JN, Johnson PW and Blaydes JP: Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription. Curr Biol. 13:1234–1239. 2003. View Article : Google Scholar : PubMed/NCBI
28	Chan CB, Liu X, Jang SW, Hsu SI, Williams I, Kang S, Chen J and Ye K: NGF inhibits human leukemia proliferation by downregulating cyclin A1 expression through promoting acinus/CtBP2 association. Oncogene. 28:3825–3836. 2009. View Article : Google Scholar : PubMed/NCBI
29	Hübler D, Rankovic M, Richter K, Lazarevic V, Altrock WD, Fischer KD, Gundelfinger ED and Fejtova A: Differential spatial expression and subcellular localization of CtBP family members in rodent brain. PLoS One. 7:e397102012. View Article : Google Scholar : PubMed/NCBI
30	Birts CN, Harding R, Soosaipillai G, Halder T, Azim-Araghi A, Darley M, Cutress RI, Bateman AC and Blaydes JP: Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance. Biol Cell. 103:1–19. 2010. View Article : Google Scholar : PubMed/NCBI
31	Paliwal S, Pande S, Kovi RC, Sharpless NE, Bardeesy N and Grossman SR: Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol. 26:2360–2372. 2006. View Article : Google Scholar : PubMed/NCBI
32	Muniz VP, Barnes JM, Paliwal S, Zhang X, Tang X, Chen S, Zamba KD, Cullen JJ, Meyerholz DK, Meyers S, et al: The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis. Mol Cancer Res. 9:867–877. 2011. View Article : Google Scholar : PubMed/NCBI
33	Guan C, Shi H, Wang H, Zhang J, Ni W, Chen B, Hou S, Yang X, Shen A and Ni R: CtBP2 contributes to malignant development of human esophageal squamous cell carcinoma by regulation of p16INK4A. J Cell Biochem. 114:1343–1354. 2013. View Article : Google Scholar : PubMed/NCBI